MUC2 and cancer: Although loss of the anti-inflammatory effects of MUC2 causes inflammatory bowel disease and CRC in the early stage, high MUC2 expression may affect treatment efficacy through specific factors secreted from the tumor microenvironment, which could partially underlie the complicated role of inflammation in cancer progression.